Journal of Global Oncology | 2019
Development of hematologic toxicity with sequential treatment of Y90 followed by PRRT in five patients at single institution with metastatic neuroendocrine patients.
Abstract
81Background: In metastatic neuroendocrine tumors (NET) peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogues (Lu-177-DOTATATE) and selective intra-arterial radio-t...